high dose amoxicillin/clavulanate — Competitive Intelligence Brief

high dose amoxicillin/clavulanate (high dose amoxicillin/clavulanate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); beta-lactamase Infectious Disease Small molecule

Target snapshot

high dose amoxicillin/clavulanate (high dose amoxicillin/clavulanate) — Albany Medical College. Amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while clavulanate inhibits beta-lactamase enzymes to prevent antibiotic degradation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
high dose amoxicillin/clavulanate TARGET	high dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase
standard dose amoxicillin/clavulanate	standard dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Amoxicillin clavulanic	Amoxicillin clavulanic	Hospital Italiano de Buenos Aires	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Imipenem+Relebactam	Imipenem+Relebactam	Wake Forest University Health Sciences	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (imipenem); serine beta-lactamases (relebactam)
Amoxicillin and Clavulanic Acid	Amoxicillin and Clavulanic Acid	Maggiore Bellaria Hospital, Bologna	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Piperacillin / Tazobactam Injection	Piperacillin / Tazobactam Injection	Rambam Health Care Campus	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins; bacterial beta-lactamase enzymes
amoxicillin/clavulanate potassium 1gm	amoxicillin/clavulanate potassium 1gm	GlaxoSmithKline	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class